Step Therapy Requirements for Provider Administered Specialty Medications

The medications listed in the table below need step therapy. However, the following criteria must be met:

› The medication is a provider administered specialty drug.

› The drug is being used to treat a medically accepted indication.

› The dose, frequency and duration of use may not exceed the safety and efficacy data supporting the medically accepted indication.

Requested Product	Codes	Preferred Alternative Agent(s) (Must try one of the following unless otherwise noted)	Codes
Alpha-1 Antitrypsin Deficiency			
Aralast NP	J0256	Prolastin C	J0256
Glassia	J0257	Zemaira	J0256
Atypical Hemolytic-Uremic Syndrome (aHUS)		Bkemv Epysqli	Q5152 Q5151
Soliris	J1299	Ultomiris	J1303
Autoimmune Infused/Other			
Actemra IV	J3262		
Avtozma IV	Q5156		
tocilizumab-anoh IV	Q5156		
Cosentyx IV	J3247		
Imuldosa IV	Q5098	Cimzia	J0717
Omvoh IV	J2267	Entyvio IV	J3380
Otulfi IV	Q9999	Ilumya	J3245
ustekinumab-aauz IV	Q9999	Orencia IV	J0129
Pyzchiva IV	Q9997	Simponi Aria	J1602
ustekinumab-ttwe IV	Q9997	Skyrizi IV	J2327
Selarsdi IV	Q9998	Stelara IV	J3358
ustekinumab-aekn IV	Q9998	ustekinumab IV	J3358
Starjemza IV	J3590	Tofidence IV	Q5133
Steqeyma IV	Q5099	Tremfya IV	J1628
ustekinumab-stba IV	Q5099		
Tyenne IV	Q5135		
tocilizumab-aazg IV	Q5135		
Wezlana IV	Q5138		
Yesintek IV	Q5100		

Bevacizumab Products			
Alymsys	Q5126	**» For oncology indications only –**	
Avastin	J9035		
Avzivi	TBD	Mvasi or	Q5107
Jobevne	Q5160	Zirabev	Q5118
Vegzelma	Q5129		
Botulinum Toxins		**» For non-cosmetic* indications only –**	
Dysport	J0586		
Myobloc	J0587	Botox	J0585
		Daxxify	J0589
		Xeomin	J0588
Generalized Myasthenia Gravis			
Bkemv	Q5152		
Epysqli	Q5151		
Imaavy	J9256	Vyvgart	J9332
Rystiggo	J9333	Vyvgart Hytrulo	J9334
Soliris	J1299		
Ultomiris	J1303		
Hyaluronic Acid Derivatives			
Durolane	J7318		
Gel-One	J7326		
Gelsyn	J7328		
GenVisc 850	J7320		
Hyalgan	J7321		
Hymovis	J7322		
Hymovis One	J7322	Synvisc/Synvisc One	J7325
Monovisc	J7327	Euflexxa	J7323
Orthovisc	J7324		
Supartz FX	J7321		
Synojoynt	J7331		
Triluron	J7332		
TriVisc	J7329		
Visco-3	J7321		
Infliximab Products			
Avsola	Q5121		
Remicade	J1745	infliximab	J1745
Renflexis	Q5104	Inflectra	Q5103
Zymfentra	J1748		

Long-acting Growth Colony Stimulating Products Fylnetra Nyvepria Rolvedon Ryzneuta Stimufend Udenyca Udenyca Onbody Ziextenzo	 Q5130 Q5122 J1449 J9361 Q5127 Q5111 Q5111 Q5120	**» Does not apply for patients using a pegfilgrastim biosimilar or Rolvedon for any indication not shared with Fulphila or Neulasta/Neulasta Onpro** Fulphila Neulasta/Neulasta Onpro	 Q5108 J2506
Lysosomal Storage Disorder Agents VPRIV	 J3385	Cerezyme Elelyso	J1786 J3060
Multiple Sclerosis (Infused) Lemtrada Ocrevus Zunovo Tyruko	 J0202 J2351 Q5134	Briumvi Ocrevus Tysabri	J2329 J2350 J2323
Neuromyelitis Optica Spectrum Disorder (NMOSD) Soliris	 J1299	Riabni Rituxan Ruxience Truxima Uplizna	Q5123 J9312 Q5119 Q5115 J1823
Paroxysmal Nocturnal Hemoglobinuria (PNH) PiaSky Soliris	 J1307 J1299	Bkemv Epysqli Ultomiris	Q5152 Q5151 J1303
Retinal Disorder Agents Ahzantive Beovu Cimerli Enzeevu Eydenzelt Lucentis Opuviz Pavblu Susvimo Vabysmo Visudyne Yesafili	 Q5150 J0179 Q5128 Q5149 TBD J2778 Q5153 Q5147 J2779 J2777 J3396 Q5155	 Avastin **Then one of the following:** Byooviz Eylea Eylea HD	 J9035/C9257 Q5124 J0178 J0177
Rituximab Products Riabni Rituxan Rituxan Hycela	 Q5123 J9312 J9311	~~**» For Rituxan, step therapy does not apply for Pemphigus Vulgaris**~~ Truxima Ruxience	 Q5115 Q5119

Somatostatin Analogues		**» For all indications except Cushing's Disease**	
lanreotide acetate	J1932	Somatuline Depot	J1930
Signifor LAR	J2502	lanreotide acetate	J1930
		Sandostatin LAR	J2353
		octreotide acetate inj. susp.	J2353
Trastuzumab Products			
Herceptin	J9355		
Herceptin Hylecta	J9356		
Hercessi	Q5146	Trazimera	Q5116
Herzuma	Q5113	Kanjinti	Q5117
Ogivri	Q5114		
Ontruzant	Q5112		

*Excluded from coverage

Exceptions

Members (enrollees) may request an exception from the plan's step therapy requirement to access a provider administered specialty drug, which is reviewed through our organization's determination process.